The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use and clinical outcomes of androgen receptor inhibitors (ARIs) for non-metastatic castration resistant prostate cancer (nmCRPC) at labeled doses in Japan.
 
Kazuhiro Suzuki
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Janssen; Merck; MSD; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Takeda
Research Funding - Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Nippon Shinyaku; Sanofi; Takeda
 
Nasreen Khan
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer
 
Tomoyuki Taguchi
Employment - Bayer
 
Kana Hattori
Employment - Bayer
 
Guifang Chen
Employment - Bayer
 
Mercedeh Ghadessi
Employment - Bayer
 
Niculae Constantinovici
Employment - Bayer
 
Vanessa Quintero
Employment - Bayer
 
Hiroyoshi Suzuki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Janssen Oncology; Janssen Research & Development; Lilly; MSD K.K; Nihon Medi-Physics; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Daiichi-Sankyo; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); Nihonkayaku (Inst)